8-K: Cognition Therapeutics' Zervimesine Shows Promise in Phase 2 Geographic Atrophy Study

Cognition Therapeutics announces positive futility analysis results from its Phase 2 MAGNIFY trial of zervimesine (CT1812) in geographic atrophy, indicating slower lesion growth in treated patients compared to placebo.

Summary

• Cognition Therapeutics reported positive results from a pre-defined futility analysis of its Phase 2 MAGNIFY trial of zervimesine (CT1812) in patients with geographic atrophy (GA).
• The analysis, conducted on the first 57 participants who completed at least 6 months of dosing, showed that zervimesine-treated patients experienced a slower lesion growth rate than those on placebo.
• The company is concluding the MAGNIFY study early to preserve financial resources and redeploy them to other indications.
• A complete analysis of the study, including 12 months of dosing, will be provided in the second quarter of 2025.
• Cognition's Phase 2 SHIMMER study in dementia with Lewy bodies (DLB) met its primary endpoint of safety and tolerability, with zervimesine-treated participants performing better than placebo-treated patients on several neuropsychiatric and motor function assessments.
• The Phase 2 SHINE study of zervimesine in Alzheimer's disease also met its primary endpoint of safety and tolerability, with a biomarker-defined subgroup experiencing a 95% reduction of cognitive decline relative to placebo.
• The company plans to schedule end-of-Phase 2 meetings with the FDA to discuss the design of registrational studies in Alzheimer's disease and DLB.

Sentiment

Score: 7

Explanation: The document presents positive results from a futility analysis and Phase 2 studies, suggesting potential efficacy and safety of zervimesine. However, it also includes forward-looking statements and risk factors, indicating that future results are not guaranteed.

Positives

• Zervimesine demonstrated a slower lesion growth rate in geographic atrophy patients compared to placebo in the Phase 2 MAGNIFY trial's futility analysis.
• The Phase 2 SHIMMER study in DLB met its primary endpoint of safety and tolerability, with positive results on multiple assessments.
• The Phase 2 SHINE study in Alzheimer's disease met its primary endpoint of safety and tolerability, with a significant reduction in cognitive decline in a biomarker-defined subgroup.
• Concluding the MAGNIFY study early allows the company to preserve financial resources for other indications.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include competition, the ability to secure funding, the ability to advance product candidates through clinical trials, and the timing and likelihood of regulatory approvals.

Future Outlook

Cognition Therapeutics plans to provide a complete analysis of the MAGNIFY study in the second quarter of 2025 and schedule end-of-Phase 2 meetings with the FDA to discuss the design of registrational studies in Alzheimer's disease and DLB.

Management Comments

• The Company continues to believe that zervimesine has the potential to alter the biological processes that contribute to dry AMD.

Industry Context

The development of zervimesine targets significant unmet needs in neurodegenerative diseases like Alzheimer's and DLB, where current treatments offer limited efficacy. The focus on slowing disease progression by targeting protein buildup aligns with a growing trend in the industry.

Comparison to Industry Standards

• The reported 95% reduction of cognitive decline in a biomarker-defined subgroup of the SHINE study, as measured by ADAS-Cog 11 relative to placebo, is a notable result when compared to other Alzheimer's drug trials.
• For example, Aduhelm, another Alzheimer's drug, showed a more modest slowing of cognitive decline in its clinical trials.
• Similarly, the improvements seen in the SHIMMER study in DLB across multiple neuropsychiatric and motor function assessments are encouraging when compared to the limited treatment options currently available for this condition.

Stakeholder Impact

• Positive results could benefit shareholders through increased stock value.
• Successful development of zervimesine could provide a new treatment option for patients with geographic atrophy, Alzheimer's disease, and dementia with Lewy bodies.
• Employees may benefit from the company's progress and potential growth.

Next Steps

• Complete analysis of the MAGNIFY study in the second quarter of 2025.
• Schedule end-of-Phase 2 meetings with the FDA to discuss the design of registrational studies in Alzheimer's disease and DLB.

Key Dates